Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer
Adagene (NASDAQ:ADAG) anticipates Phase II data for its CTLA-4 therapy in MSS colorectal cancer, aiming to replicate Phase Ib response rates of 17-25%. The company plans FDA meetings post-Phase II and potential Phase III trials. Adagene also has a neoadjuvant study in Singapore, with results expected in 2027. It collaborates with Incyte on a combination therapy and has a cash runway into 2028.
How this was made

The 30-second read
Why it matters
The announcement of Phase II plans and cash runway provides new information for valuation models but does not create an immediate trade trigger.
Market read
Provides early insight into upcoming trial data and financial runway, useful for biotech-focused investors.
What to watch
Potential competition from other CTLA-4 or bispecific programs and regulatory timelines.
Background
Adagene (NASDAQ:ADAG) is a clinical‑stage biotech developing masked antibody therapies. The company recently raised cash in a follow‑on offering.
Ticker impact
Adagene announced plans to generate Phase II data for its masked CTLA-4 therapy ADG126 in MSS colorectal cancer and disclosed a cash runway into H2 2028.
potential upside if Phase II results are favorable, otherwise pressure from uncertainty
The article provides first‑report details on upcoming trial milestones and cash resources, but no concrete results yet.
Market effects
May influence investor sentiment toward early‑stage immunotherapy biotech peers.
Limited to US‑listed biotech sector.
Low global impact; primarily relevant to specialty biotech investors.
Counterpoint
Investors could short on the basis that the trial may fail and cash burn could become a concern.
Key entities
- companyAdagene Inc.
Clinical‑stage biopharma developing masked CTLA-4 therapy ADG126.
- companyIncyte
Partner in a PD‑1/TIGIT bispecific collaboration with Adagene.